Pfizer
Compare Pfizer…Diversified pharma re-entering obesity via M&A: acquired Metsera November 2025 (~$7.3B upfront + up to $3.5B contingent) after danuglipron failed. Sciwind partnership ($495M) for ecnoglutide in China.
SectorsGLP-1
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
PfizerDiversified pharma re-entering obesity via M&A: acquired Metsera November 2025 (~$7.3B upfront + up to $3.5B contingent) after danuglipron failed. Sciwind partnership ($495M) for ecnoglutide in China.
Quarterly breakdown of revenue by product line and service category
2021-Q2 — 2026-Q1
Quarterly breakdown of revenue by geographic region
2021-Q2 — 2026-Q1
Data from SEC filings via FMP • 55 periods available